SARS-CoV-2 : Point-of-Care companies are racing to provide rapid and actionable tests
“The past few months have seen a new biological threat, the COVID-19 infection, also called new coronavirus, and caused by the SARS-CoV-2 virus, which has reshaped the entire diagnostics ecosystem” says Sébastien Clerc, Technology & Market Analyst, Microfluidics, Sensing & Actuating at Yole Développement (Yole). “As the epidemic has slowed down in China, it is Europe’s and the USA’s turn to be suffering. As a direct consequence, there is a strong demand for diagnostics tests to rapidly identify infected people and numerous companies started developing such tests, including companies relying on microfluidic technologies. In a few weeks, tens of tests were ready”.
The opportunity looks huge for diagnostics companies, but is the supply chain ready for mass-production of these tests in addition to their usual business or will it impact the production of other types of tests?
The pandemic poses interesting questions regarding the length of development, approval and manufacturing of tests when we have no time to waste but that reliability cannot be compromised. It will be imperative to analyze how these issues will be addressed once the pandemic will be behind us.
In this context, the market research & strategy consulting company Yole, intensively analyses the Point-of-Need market and technologies and offers a comprehensive understanding of the industry in the Point-of-Need 2020 – Including PCR-Based Testing report. Aiming to provide an overview of what microfluidic technology offers to Point-of-Need testing, this report includes new major trends and evolution, market and revenue forecasts, and supply chain description and analysis.
Everything that has to deal with human health has to face very slow regulatory processes, which are not adapted in the current emergency context… More info.